Nociscan is designed to locate the source of chronic lower back pain.
In a corporate update, the company shared key milestones including multiple partnerships with spine surgeon leaders in the U.S., significant payer coverage in the U.K. and having more than $50 million invested into the platform.
Nociscan’s technology is also protected by 23 U.S. patents, 17 international patents, and there are 12 pending patent applications.
“We are excited with the recent positive success we have been awarded as Aclarion has consistently achieved stated catalysts of value creation that fall into a very concise framework proven to bring disruptive technological advancements to standard of care in the healthcare sector,” Brent Ness, Aclarion CEO, said in the release.
